中药热熨敷技术干预肺癌化疗患者癌因性疲乏的效果及机制探讨

注册号:

Registration number:

ChiCTR2300073007 

最近更新日期:

Date of Last Refreshed on:

2023-08-23 11:06:40 

注册时间:

Date of Registration:

2023-06-29 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

中药热熨敷技术干预肺癌化疗患者癌因性疲乏的效果及机制探讨

Public title:

Discussion on the effect and mechanism of TCM Hot Ironing Compress on cancer related fatigue patients with lung cancer chemotherapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

中药热熨敷技术干预肺癌化疗患者癌因性疲乏的效果及机制探讨

Scientific title:

Discussion on the effect and mechanism of TCM Hot Ironing Compress on cancer related fatigue patients with lung cancer chemotherapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王玉慧 

研究负责人:

郭敬 

Applicant:

Wang Yuhui 

Study leader:

Guo Jing 

申请注册联系人电话:

Applicant telephone:

+86 133 1155 5261

研究负责人电话:

Study leader's
telephone:

+86 136 1116 3517

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

393014377@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1969guoj@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区北线阁5号中国中医科学院广安门医院 肿瘤科

研究负责人通讯地址:

北京市西城区北线阁5号中国中医科学院广安门医院 护理部

Applicant address:

5 Beixiange, Xicheng District, Beijing

Study leader's address:

5 Beixiange, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100053

研究负责人邮政编码:

Study leader's postcode:

100053

申请人所在单位:

中国中医科学院广安门医院

Applicant's institution:

Guang'anmen Hospital

研究负责人所在单位:

中国中医科学院广安门医院

Affiliation of the Leader:

Guang'anmen Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-036-KY

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国中医科学院广安门医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guang'anmen Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-03-04 00:00:00

伦理委员会联系人:

乔洁

Contact Name of the ethic committee:

Qiao Jie

伦理委员会联系地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Contact Address of the ethic committee:

5 Beixiange, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8800 1552

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gamhec@126.com

研究实施负责(组长)单位:

中国中医科学院广安门医院

Primary sponsor:

Guang'anmen Hospital

研究实施负责(组长)单位地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Primary sponsor's address:

5 Beixiange, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

西城区

Country:

China

Province:

Beijing

City:

Xicheng District

单位(医院):

中国中医科学院广安门医院

具体地址:

北京市西城区北线阁5号中国中医科学院广安门医院

Institution
hospital:

Guang'anmen Hospital

Address:

5 Beixiange, Xicheng District, Beijing

经费或物资来源:

院拨经费

Source(s) of funding:

funding from own academy

研究疾病:

肺癌  

Target disease:

Lung cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

选择第2及以上周期化疗伴轻/中度CRF肺癌患者为研究对象,采用前瞻性、多中心、大样本、随机对照临床实验研究方法,干预组在对照组护理方法的基础上,应用结合肺癌化疗患者特点的中药热熨敷技术方案,通过分析疲乏程度、生存质量、KPS评分的改善情况、不良事件发生率,评价中药热熨敷技术对CRF的作用效果及安全性;分析血液相关免疫指标,探讨中药热熨敷干预CRF的作用机制,以期形成高质量的研究证据及可推广的技术方案。  

Objectives of Study:

Patients with lung cancer accompanied by mild/moderate CRF during the second or above cycle of chemotherapy were selected as the research objects, and a prospective, multi-center, large-sample, randomized controlled clinical trial was adopted. The intervention group, on the basis of the nursing method of the control group, was applied TCM Hot Ironing Compress combined with the characteristics of lung cancer chemotherapy patients. The effect and safety of TCM Hot Ironing Compress technique on CRF were evaluated by analyzing fatigue degree, quality of life, improvement of KPS score and incidence of adverse events. The blood related immune indexes were analyzed to explore the mechanism of Chinese medicine hot ironing in the intervention of CRF, in order to form high-quality research evidence and technical schemes that can be promoted.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并严重的心、肝、肾功能异常; 2.出、凝血功能异常; 3.局部皮肤炎症、疤痕、破损; 4.正在使用生血丸/参芪扶正注射液/贞芪扶正颗粒等扶正益气类中药或保健品,影响疗效判定者; 5.正在接受同步放疗的患者; 6.其他中药热熨敷的禁忌证。

Exclusion criteria:

1. Complicated with serious abnormality of heart, liver and kidney function; 2. Abnormal bleeding and coagulation function; 3. Local skin inflammation, scar, damage; 4. Those who are using shengxue pill, Shenqi Fuzheng Injection, Zhenqi Fuzheng granule and other fuzheng supplementing traditional Chinese medicine or health care products, affecting the efficacy evaluation; 5. Patients undergoing synchronous radiotherapy; 6. Other contraindications of TCM Hot Ironing Compress.

研究实施时间:

Study execute time:

From 2021-10-01 00:00:00 To 2024-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-18 00:00:00 To 2024-09-30 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

110

Group:

Intervention group

Sample size:

干预措施:

中药热熨敷+常规疾病和症状护理措施

干预措施代码:

Intervention:

TCM Hot Ironing Compress + Conventional diseases and symptoms nursing measures

Intervention code:

组别:

对照组

样本量:

110

Group:

control group

Sample size:

干预措施:

常规疾病和症状护理措施

干预措施代码:

Intervention:

Conventional diseases and symptoms nursing measures

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

西城区 

Country:

China

Province:

Beijing

City:

Xicheng District

单位(医院):

中国中医科学院广安门医院 

单位级别:

三级甲等医院 

Institution
hospital:

Guang'anmen Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京市 

市(区县):

海淀区 

Country:

China

Province:

Beijing

City:

Haidian District

单位(医院):

中国中医科学院西苑医院 

单位级别:

三级甲等医院 

Institution
hospital:

Xiyuan Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京市 

市(区县):

朝阳区 

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

中国中医科学院望京医院 

单位级别:

三级甲等医院 

Institution
hospital:

Wangjing Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疲乏程度

指标类型:

主要指标

Outcome:

the fatigue degree

Type:

Primary indicator

测量时间点:

干预第0天、第3天、第7天、第14天、第21天

测量方法:

采用Piper疲乏量表中文修订版

Measure time point of outcome:

Intervention day 0, day3, day 7, day 14, day21

Measure method:

RPFS

指标中文名:

生存质量

指标类型:

次要指标

Outcome:

quality of life

Type:

Secondary indicator

测量时间点:

干预第0天、第7天、第14天、第21天

测量方法:

采用癌症患者生存质量测评问卷

Measure time point of outcome:

Intervention day 0, day 7, day 14, day21

Measure method:

EORTC QLQ-c30 (V3.0)

指标中文名:

卡氏评分

指标类型:

次要指标

Outcome:

Karnofsky

Type:

Secondary indicator

测量时间点:

干预第0天、第3天、第7天、第14天、第21天

测量方法:

采用Kamofsky(卡氏,KPS)功能状态评分标准进行评价

Measure time point of outcome:

Intervention day 0, day3, day 7, day 14, day21

Measure method:

KPS

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 19 years
最大 Max age 79 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由课题组数据管理组负责人从随机数字表中任意1个数字开始向右,顺次抄录220组数字(规定所选数字为三位数),将单数划为干预组,双数划为对照组,两组例数不等时,再继续查随机数字表,将其除以数量较多一组的例数,得余数n,则数量较多组中的第n位受试者需调至另一组,若仍不等,依照上述方法进一步操作,直至两组例数一致。

Randomization Procedure (please state who generates the random number sequence and by what method):

By research data management group head of any one from a random number table Numbers began to the right, progressive transcribing 220 number (regulation for the selected for three digits), the singular is divided into intervention group and the bottom is divided into the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台:http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform: http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.数据采集:数据的采集工作由经过系统培训及考核的临床实施组完成采集及CRF上所有数据的填写。 2.数据管理:患者观察周期结束,CRF表所有项目均填写完毕后,应先交由数据管理组成员双人核对录入电子版病例记录表及ResMan临床试验公共管理平台。整个项目的数据管理工作由数据管理组统一负责。所有纸质版数据均统一安全存放,电子版数据设置打开密码存放至数据管理组电脑,打开密码不可外漏。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Data collection: Data collection was completed by the clinical implementation group that had been systematically trained and assessed and all data were filled in on the CRF. 2. Data Management: After the patient observation period is over and all items in the CRF form are filled in, it should be checked by two members of the data management team and entered into the electronic case record form and ResMan Clinical Trial Public Management platform. The data management team is responsible for the data management of the whole project. All paper data are stored in a unified and safe manner, and the password for opening electronic data is stored in the computer of the data management group, and the password cannot be leaked.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-06-29 16:15:19